DOCSLIB.ORG

Management of Major Depressive Disorder with Psychotic Features

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Major Depressive Disorder with Psychotic Features Savvy Psychopharmacology Management of major depressive disorder with psychotic features Rachel Barr, PharmD, BCPP, Ben Miskle, PharmD, and Christopher Thomas, PharmD, BCPS, BCPP rs. C, age 56, has a history of major Based on her presentation and response, depressive disorder (MDD). She what do the data suggest about her length M has been stable for 5 years without of treatment, and when should you consider medication. Six months ago, she presented tapering the antipsychotic medication? to you, along with her son, seeking help. She reported that she had been experienc- In DSM-5, MDD with psychotic features ing insomnia, fatigue, and was not engag- is a severe subtype of MDD that is defined Vicki L. Ellingrod, ing in hobbies. Her son told you that his as a major depressive episode character- PharmD, FCCP mother had lost weight and had been avoid- ized by delusions and/or hallucinations.1 Department Editor ing family dinners. Mrs. C reported recurrent In the general population, the lifetime thoughts of dying and heard voices vividly prevalence of this disorder varies from telling her that she was a burden and that 0.35% to 1%, and the rate is higher in older her family would be better off without her. patients.2 Risk factors include female However, there was no imminent danger of gender, family history, and concomitant self-harm. At that appointment, you initiated bipolar disorder.2 sertraline, 50 mg/d titrated to 100 mg/d, and olanzapine, 5 mg/d. Since that time, Mrs. C has followed up Practice Points with you monthly with good response to • In patients experiencing major depressive disorder (MDD) with psychotic features, the medications. Currently, she states her consider electroconvulsive therapy or depression is much improved, and she an antidepressant in combination with denies hearing voices for approximately an antipsychotic. 5 months. • Any antipsychotic can be considered for the Dr. Barr is a Clinical Psychiatric Pharmacist, Eastern Oklahoma treatment of MDD with psychotic features VA Healthcare System, Tulsa, Oklahoma. Dr. Miskle is a Clinical because there are no head-to-head trials. Psychiatric Pharmacist, University of Iowa Hospitals and Clinics, Iowa and Clinical Assistant Professor, University of Iowa College However, because second-generation of Pharmacy, Iowa City, Iowa. Dr. Thomas is Director, PGY-1 antipsychotics have a lower risk of and PGY-2 Residency Programs, Clinical Pharmacy Specialist in adverse effects, they should be preferred Psychiatry, Chillicothe VA Medical Center, Chillicothe, Ohio, and to first-generation antipsychotics. Savvy Psychopharmacology Clinical Associate Professor of Pharmacology, Ohio University is produced in partnership College of Osteopathic Medicine, Athens, Ohio. • When prescribing combination therapy, with the College Disclosures continue treatment for at least 9 months of Psychiatric The contents of this article do not represent the views of the US to reduce the risk of relapse, and consider and Neurologic Department of Veterans Affairs or the US Government. This material Pharmacists is the result of work supported with resources and the use of facilities reducing the dose of the antipsychotic cpnp.org at the Chillicothe Veterans Affairs Medical Center in Chillicothe, Ohio. medication after 1 year of treatment. mhc.cpnp.org (journal) The case presented in this article is fictional and does not represent a specific case or person(s). • When stopping antipsychotic therapy, The authors report no financial relationships with any companies implement a slow and gradual taper whose products are mentioned in this article, or with manufacturers to allow for assessment of symptom of competing products. Current Psychiatry recurrence. 30 February 2021 doi: 10.12788/cp.0092 Savvy Psychopharmacology Epidemiologic studies have shown that setting.6 In another study, the combination psychotic features can occur in 15% to of olanzapine and fluoxetine was also found 20% of patients with MDD. The psychotic to be superior to olanzapine monotherapy features that occur during these episodes in reducing Hamilton Depression Rating are delusions and hallucinations.1 These Scale (HAM-D) scores.7 Quetiapine, when features can be either mood-congruent used in combination with venlafaxine, was (related to the depressive themes of worth- found to be superior to venlafaxine mono- lessness or guilt) or mood-incongruent (ie, therapy in response.8 Lastly, amitriptyline in unrelated to depressive themes).1 combination with either haloperidol or per- phenazine has been shown to be superior to Treatment options: monotherapy.9,10 However, no medications ECT or pharmacotherapy are specifically FDA-approved for the indi- Guidelines from the American Psychiatric cation of depression with psychotic features. Clinical Point 3 Association and the National Institute for Because none of these agents have been ECT can provide Clinical Excellence4 recommend treating compared in head-to-head trials, any com- depression with psychosis with electro- bination of antidepressant and antipsychotic rapid and significant convulsive therapy (ECT) or with com- medication can be used. Due to the greater improvement in bined antidepressant and antipsychotic risk of adverse effects with first-generation patients with severe medications as first-line options. The Texas antipsychotics (FGAs), such as extrapyra- psychosis, suicidality, Medication Algorithm Project (TMAP) midal symptoms (EPS), second-generation or risk of imminent Algorithm for MDD,5 which closely antipsychotics (SGAs) should be trialed first. focuses on treatment of MDD with psy- harm chotic features, can be used for treatment How long should treatment last? decisions (see Related Resources, page 32). The optimal timeline for treating patients Electroconvulsive therapy is known to be with MDD with psychotic features is efficacious in treating patients with MDD unknown. According to the TMAP algo- with psychotic features and should be con- rithm and expert opinion, the continuation sidered as a treatment option. However, phase of pharmacotherapy should include medication therapy is often chosen as the treatment for at least 4 months with an anti- initial treatment due to the limitations of psychotic medication and at least 2 years to ECT, including accessibility, cost, and patient lifetime treatment with an antidepressant.5 preference. However, in certain cases, ECT The STOP-PD II study, which was a con- is the preferred option because it can pro- tinuation of the 12-week STOP-PD study, vide rapid and significant improvement in examined antipsychotic duration to deter- patients with severe psychosis, suicidality, mine the effects of continuing olanzapine or risk of imminent harm. once an episode of psychotic depression Pharmacotherapy for the treatment of had responded to olanzapine and sertra- MDD with psychotic features should consist line.11 Patients who had achieved remission of a combination of an antidepressant and after receiving olanzapine and sertraline antipsychotic medication. This combination were randomized to continue to receive this has been shown to be more effective than combination or to receive sertraline plus either agent alone. Some combinations have placebo for 36 weeks. The primary outcome Discuss this article at been studied specifically for MDD with psy- was relapse, which was broadly defined as www.facebook.com/ MDedgePsychiatry chosis. The Study of the Pharmacotherapy of 1 of the following11: Psychotic Depression (STOP-PD), a 12-week, • a Structured Clinical Interview for double-blind, randomized controlled trial, the DSM (SCID)-rated assessment that found that the combination of sertraline and revealed the patient had enough symp- olanzapine was efficacious and superior to toms to meet criteria for a DSM-IV major Current Psychiatry monotherapy with olanzapine in an acute depressive episode Vol. 20, No. 2 31 continued Savvy Psychopharmacology antidepressants plus antipsychotics are Related Resources often utilized as an initial treatment. • Texas Medication Algorithm Project. Algorithm for the Essentially, any antipsychotic agent can treatment of major depressive disorder with psychotic features. https://chsciowa.org/sites/chsciowa.org/files/ be prescribed in conjunction with an anti- resource/files/9_-_depression_med_algorithm_ depressant, but due to the greater risk of supplement.pdf adverse effects associated with FGAs, • Dold M, Bartova L, Kautzky A, et al. Psychotic features in patients with major depressive disorder: a report from the SGAs should be trialed first. The results European Group for the Study of Resistant Depression. of the STOP-PD6 and STOP-PD II11 studies J Clin Psychiatry. 2019;80(1):17m12090. doi: 10.4088/ JCP.17m12090 have shown that once a patient responds • Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of to an antidepressant and antipsychotic, continuing olanzapine vs placebo on relapse among combination therapy needs to continue patients with psychotic depression in remission: the STOP-PD II randomized clinical trial. JAMA. 2019;322(7): for at least 9 months to reduce the risk of Clinical Point 622-631. relapse. Thereafter, reducing the dose of When prescribing Drug Brand Names the antipsychotic can be considered after 1 Amitriptyline • Elavil, Endep Quetiapine • Seroquel year of treatment; however, no data exist combination Fluoxetine • Prozac Sertraline • Zoloft about which agent and tapering schedule Haloperidol • Haldol Venlafaxine • Effexor therapy, continue Olanzapine • Zyprexa to consider. Because no optimal
Load more

Recommended publications
  • First Episode Psychosis an Information Guide Revised Edition
    First episode psychosis An information guide revised edition Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) i First episode psychosis An information guide Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) A Pan American Health Organization / World Health Organization Collaborating Centre ii Library and Archives Canada Cataloguing in Publication Bromley, Sarah, 1969-, author First episode psychosis : an information guide : a guide for people with psychosis and their families / Sarah Bromley, OT Reg (Ont), Monica Choi, MD, Sabiha Faruqui, MSc (OT). -- Revised edition. Revised edition of: First episode psychosis / Donna Czuchta, Kathryn Ryan. 1999. Includes bibliographical references. Issued in print and electronic formats. ISBN 978-1-77052-595-5 (PRINT).--ISBN 978-1-77052-596-2 (PDF).-- ISBN 978-1-77052-597-9 (HTML).--ISBN 978-1-77052-598-6 (ePUB).-- ISBN 978-1-77114-224-3 (Kindle) 1. Psychoses--Popular works. I. Choi, Monica Arrina, 1978-, author II. Faruqui, Sabiha, 1983-, author III. Centre for Addiction and Mental Health, issuing body IV. Title. RC512.B76 2015 616.89 C2015-901241-4 C2015-901242-2 Printed in Canada Copyright © 1999, 2007, 2015 Centre for Addiction and Mental Health No part of this work may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system without written permission from the publisher—except for a brief quotation (not to exceed 200 words) in a review or professional work. This publication may be available in other formats. For information about alterna- tive formats or other CAMH publications, or to place an order, please contact Sales and Distribution: Toll-free: 1 800 661-1111 Toronto: 416 595-6059 E-mail: [email protected] Online store: http://store.camh.ca Website: www.camh.ca Disponible en français sous le titre : Le premier épisode psychotique : Guide pour les personnes atteintes de psychose et leur famille This guide was produced by CAMH Publications.
    [Show full text]
  • Is Your Depressed Patient Bipolar?
    J Am Board Fam Pract: first published as 10.3122/jabfm.18.4.271 on 29 June 2005. Downloaded from EVIDENCE-BASED CLINICAL MEDICINE Is Your Depressed Patient Bipolar? Neil S. Kaye, MD, DFAPA Accurate diagnosis of mood disorders is critical for treatment to be effective. Distinguishing between major depression and bipolar disorders, especially the depressed phase of a bipolar disorder, is essen- tial, because they differ substantially in their genetics, clinical course, outcomes, prognosis, and treat- ment. In current practice, bipolar disorders, especially bipolar II disorder, are underdiagnosed. Misdi- agnosing bipolar disorders deprives patients of timely and potentially lifesaving treatment, particularly considering the development of newer and possibly more effective medications for both depressive fea- tures and the maintenance treatment (prevention of recurrence/relapse). This article focuses specifi- cally on how to recognize the identifying features suggestive of a bipolar disorder in patients who present with depressive symptoms or who have previously been diagnosed with major depression or dysthymia. This task is not especially time-consuming, and the interested primary care or family physi- cian can easily perform this assessment. Tools to assist the physician in daily practice with the evalua- tion and recognition of bipolar disorders and bipolar depression are presented and discussed. (J Am Board Fam Pract 2005;18:271–81.) Studies have demonstrated that a large proportion orders than in major depression, and the psychiat- of patients in primary care settings have both med- ric treatments of the 2 disorders are distinctly dif- ical and psychiatric diagnoses and require dual ferent.3–5 Whereas antidepressants are the treatment.1 It is thus the responsibility of the pri- treatment of choice for major depression, current mary care physician, in many instances, to correctly guidelines recommend that antidepressants not be diagnose mental illnesses and to treat or make ap- used in the absence of mood stabilizers in patients propriate referrals.
    [Show full text]
  • The Implications of Hypersomnia in the Context of Major Depression: Results from a Large, International, Observational Study
    ARTICLE IN PRESS JID: NEUPSY [m6+; March 2, 2019;10:45 ] European Neuropsychopharmacology (2019) 000, 1–11 www.elsevier.com/locate/euroneuro The implications of hypersomnia in the context of major depression: Results from a large, international, observational study a a, b c a A. Murru , G. Guiso , M. Barbuti , G. Anmella , a, d ,e a ,f , g g h N. Verdolini , L. Samalin , J.M. Azorin , J. Jules Angst , i j k a, l C.L. Bowden , S. Mosolov , A.H. Young , D. Popovic , m c a, ∗ a M. Valdes , G. Perugi , E. Vieta , I. Pacchiarotti , For the BRIDGE-II-Mix Study Group a Barcelona Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain b Clinica Psichiatrica, Dipartimento di Igiene e Sanità, Università di Cagliari, Italy c Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, University of Perugia, Santa Maria della Misericordia Hospital, Edificio Ellisse, 8 Piano, Sant’Andrea delle Fratte, 06132, Perugia, Italy d FIDMAG Germanes Hospitalàries Research Foundation, Sant Boi de Llobregat, Barcelona, Catalonia, Spain e Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy f CHU Clermont-Ferrand, Department of Psychiatry, University of Auvergne, Clermont-Ferrand, France g Fondation FondaMental, Hôpital Albert Chenevier, Pôle de Psychiatrie, Créteil, France h Department of Psychiatry, Psychotherapy and Psychosomatics,
    [Show full text]
  • Specificity of Psychosis, Mania and Major Depression in A
    Molecular Psychiatry (2014) 19, 209–213 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp ORIGINAL ARTICLE Specificity of psychosis, mania and major depression in a contemporary family study CL Vandeleur1, KR Merikangas2, M-PF Strippoli1, E Castelao1 and M Preisig1 There has been increasing attention to the subgroups of mood disorders and their boundaries with other mental disorders, particularly psychoses. The goals of the present paper were (1) to assess the familial aggregation and co-aggregation patterns of the full spectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contemporary diagnostic criteria; and (2) to evaluate the familial specificity of the major subgroups of mood disorders, including psychotic, manic and major depressive episodes (MDEs). The sample included 293 patients with a lifetime diagnosis of SAF disorder, bipolar disorder and major depressive disorder (MDD), 110 orthopedic controls, and 1734 adult first-degree relatives. The diagnostic assignment was based on all available information, including direct diagnostic interviews, family history reports and medical records. Our findings revealed specificity of the familial aggregation of psychosis (odds ratio (OR) ¼ 2.9, confidence interval (CI): 1.1–7.7), mania (OR ¼ 6.4, CI: 2.2–18.7) and MDEs (OR ¼ 2.0, CI: 1.5–2.7) but not hypomania (OR ¼ 1.3, CI: 0.5–3.6). There was no evidence for cross-transmission of mania and MDEs (OR ¼ .7, CI:.5–1.1), psychosis and mania (OR ¼ 1.0, CI:.4–2.7) or psychosis and MDEs (OR ¼ 1.0, CI:.7–1.4).
    [Show full text]
  • The Trauma of First Episode Psychosis: the Role of Cognitive Mediation
    The trauma of first episode psychosis: the role of cognitive mediation Chris Jackson, Claire Knott, Amanda Skeate, Max Birchwood Objective: First episode psychosis can be a distressing and traumatic event which has been linked to comorbid symptomatology, including anxiety, depression and PTSD symp- toms (intrusions, avoidance, etc.). However, the link between events surrounding a first episode psychosis (i.e. police involve- ment, admission, use of Mental Health Act, etc.) and PTSD symptoms remains unproven. In the PTSD literature, attention has now turned to the patient’s appraisal of the traumatic event as a key mediator. In this study we aim to evaluate the diagnostic status of first episode psychosis as a PTSD-triggering event and to determine the extent to which cognitive factors such as appraisals and coping mechanisms can mediate the expression of PTSD (traumatic) symptomatology. Method: Approximately 1.5 years after their first episode of psychosis, patients were assessed for traumatic symptoms, conformity to DSM-IV criteria for posttraumatic stress disorder (PTSD), and their appraisals of the traumatic events and coping strategies. Psychotic symptomatology was also measured. Results: 31% of the sample of 35 patients who agreed to participate reported symptoms consistent with a diagnosis of PTSD. Although no relationship was found between PTSD (traumatic) symptoms and potentially traumatic aspects of the first episode (including place of treatment, detention under the MHA etc.), intrusions and avoidance were positively related to retrospective appraisals of stressfulness of the ward (i.e. the more stressful they rated it the greater the number of PTSD symptoms) and the patient’s coping style (sealers were less likely to report intrusive re-experiencing but more likely to report avoidance).
    [Show full text]
  • What Is Bipolar Disorder?
    Bipolar Disorder Fact Sheet For more information about bipolar or other mental health disorders, call 513-563-HOPE or visit our website at www.lindnercenterofhope.com. What Is Bipolar Disorder? What does your mood Each year, nearly 6 million adults (or approximately 5% of the population) in the U.S. are affected by bipolar disorder, according to the Depression and Bipolar Support say about you? Alliance. While the condition is treatable, unfortunately bipolar disorder is frequently misdiagnosed and may be present an average of 10 years before it is correctly identified. Go to My Mood Monitor™, a three minute assessment Bipolar disorder (also known as bipolar depression or manic depression) is identified for anxiety, depression, PTSD by extreme shifts in mood, energy, and functioning that can be subtle or dramatic. The characteristics can vary greatly among individuals and even throughout the and bipolar disorder, at course of one individual’s life. www.mymoodmonitor.com to see if you may need a Bipolar disorder is usually a life-long condition that begins in adolescence or early professional evaluation. adulthood with recurring episodes of mania (highs) and depression (lows) that can continue for days, months or even years. My Mood Monitor™ Copyright © 2002-2010 by M3 Information™ Phases of Bipolar Disorder • Mania is the activated phase of bipolar disorder and is characterized by extreme moods, increased or impulsive mental and physical activities, and risk taking. • Hypomania describes a mild-to-moderate level of mania. Because it may feel good to the individual experiencing it, this condition can be difficult for someone with bipolar illness to recognize as a concern.
    [Show full text]
  • Social Anxiety Disorder in Psychosis: a Critical Review
    Chapter 7 Social Anxiety Disorder in Psychosis: A Critical Review Maria Michail Additional information is available at the end of the chapter http://dx.doi.org/10.5772/53053 1. Introduction Eugene Bleuler was one of the first to emphasize the importance of affect and its pro‐ nounced impact upon the course and outcome of psychosis. The famous “Krapelian dichtoco‐ my” which supported the clear distinction between mood and psychotic illnesses on the basis of etiological origins, symptomatology, course and outcome was first challenged by Bleuler. Bleuler recognized the disorders of affect as one of the four primary symptoms (blunted 'Affect', loosening of 'Associations', 'Ambivalence', and 'Autism') of schizophrenia, as opposed to delusions and hallucinations which were perceived as secondary. Bleuler further postulated the incongruity between emotions and thought content in people with schizo‐ phrenia as well as their diminished or complete lack of emotional responsiveness. Bleuler’s recognition of the importance of affective disturbances in schizophrenia has influenced cur‐ rent diagnostic definitions and criteria of schizophrenia. The sharp distinction between affect and psychosis which has dominated both research and clinical practice during the nineteenth and twentieth century has gradually been abandoned. New evidence from epidemiological, familial and molecular genetic studies (Cardno et al, 2005; Craddock et al, 2005; Craddock & Owen, 2005) have come to light demonstrating the endemic nature of affective disturbances in psychosis. In a twin study by Cardno et al (2002), the authors identified significant overlap in risk factors between the schizophrenic, schizoaffective and manic syndromes. Specifically, considerable genetic correlations were reported between the schizophrenic and manic syndromes.
    [Show full text]
  • The Clinical Presentation of Psychotic Disorders Bob Boland MD Slide 1
    The Clinical Presentation of Psychotic Disorders Bob Boland MD Slide 1 Psychotic Disorders Slide 2 As with all the disorders, it is preferable to pick Archetype one “archetypal” disorder for the category of • Schizophrenia disorder, understand it well, and then know the others as they compare. For the psychotic disorders, the diagnosis we will concentrate on will be Schizophrenia. Slide 3 A good way to organize discussions of Phenomenology phenomenology is by using the same structure • The mental status exam as the mental status examination. – Appearance –Mood – Thought – Cognition – Judgment and Insight Clinical Presentation of Psychotic Disorders. Slide 4 Motor disturbances include disorders of Appearance mobility, activity and volition. Catatonic – Motor disturbances • Catatonia stupor is a state in which patients are •Stereotypy • Mannerisms immobile, mute, yet conscious. They exhibit – Behavioral problems •Hygiene waxy flexibility, or assumption of bizarre • Social functioning – “Soft signs” postures as most dramatic example. Catatonic excitement is uncontrolled and aimless motor activity. It is important to differentiate from substance-induced movement disorders, such as extrapyramidal symptoms and tardive dyskinesia. Slide 5 Disorders of behavior may involve Appearance deterioration of social functioning-- social • Behavioral Problems • Social functioning withdrawal, self neglect, neglect of • Other – Ex. Neuro soft signs environment (deterioration of housing, etc.), or socially inappropriate behaviors (talking to themselves in
    [Show full text]
  • Major Depressive Episode
    Molina Healthcare Coding Education Major Depressive Episode Documentation Examples: Initial Diagnosis: 65 year old Latina presenting with new onset depressive symptoms for past 2 months including daily depressed mood, loss of energy and inability to concentrate. PHQ9 score of 12 (moderate depression). Assessment: Patent is newly diagnosed with major depression, single episode, moderate; needing medical and cognitive therapy Accurately diagnosing Major Depression requires distinguishing between a single depressive episode Plan: Start Citalopram 20 mg and refer for psychotherapy and recurrent depression. Hence, it is necessary to ICD-10 Code: F32.1 Major Depressive Disorder, single episode, moderate identify and document the manifestations of the disease burden. Another key consideration is noting OR the term “chronic” can apply to both recurrent and Initial Diagnosis: single depressive episodes. A single or first time event should be coded as F32.0-F32.9 (severity 73 year old female with many known episodes of Major specification required) and any patient who has Depression now complaining of worsening symptoms experienced subsequent episodes should be coded as including increased loss of interest in activities, hypersomnia, increased tearfulness and sadness. Denies F33.9. thoughts of self-harm ICD-10: F32.0-F32.5 Major Depressive Disorder, Assessment: Patient diagnosed with Major Depression, recurrent, single episode, specifier required (e.g., mild; unspecified; currently symptoms not controlled moderate; severe with or without psychotic Plan: Increase SSRI dosage and close follow- up recommended symptoms; in partial or full remission) ICD-10 Code: F33.9, Major Depressive Disorder, OR recurrent, unspecified ICD-10: F33.9 Major Depressive Disorder, recurrent, unspecified The Patient Health Questionnaire-9 (PHQ-9) is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
    [Show full text]
  • Psychotic Symptoms in Post Traumatic Stress Disorder: a Case Illustration and Literature Review
    CASE REPORT SA Psych Rev 2003;6: 21-24 Psychotic symptoms in post traumatic stress disorder: a case illustration and literature review Adekola O Alao, Laura Leso, Mantosh J Dewan, Erika B Johnson Department of Psychiatry, State University of New York, Syracuse, NY, USA ABSTRACT Posttraumatic stress disorder (PTSD) is a condition being increasingly recognized. The diagnosis is based on the re-experiencing of a traumatic event. There have been reports of the presence of psychotic symptoms in some cases of PTSD. This may represent in- creased severity or a different diagnostic clinical entity. It has also been suggested that psychotic symptoms may be over-represented in the Hispanic population. In this manuscript, we describe a case to illustrate this relationship and we review the current literature on the relationship of psychotic symptoms among PTSD patients. The implications regarding diagnosis, treatment, and prognosis are discussed. Keywords: Psychosis; PTSD; Trauma; Hallucinations; Delusions; Posttraumatic stress disorder. INTRODUCTION the best of our knowledge is the first report of psychotic symp- Posttraumatic stress disorder (PTSD) is a psychiatric illness for- toms in a non-veteran adult with PTSD. mally recognized with the publication of the third edition of the Diagnostic and Statistical Manual of the American Psychiatric CASE ILLUSTRATION Association in 1980.1 Re-experiencing of traumatic events as A 37 year-old gentleman was admitted to a state university hos- recurrent unpleasant images, nightmares, and intrusive feelings pital inpatient setting after alerting his wife of his suicidal is a core characteristic of PTSD.2 Most PTSD research has oc- thoughts and intent to slit his throat with a kitchen knife.
    [Show full text]
  • Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies
    Review Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies Alexandre González-Rodríguez 1 , Javier Labad 2 and Mary V. Seeman 3,* 1 Department of Mental Health, Parc Tauli University Hospital, Autonomous University of Barcelona (UAB), I3PT, Sabadell, 08280 Barcelona, Spain; [email protected] 2 Department of Psychiatry, Hospital of Mataró, Consorci Sanitari del Maresme, Institut d’Investigació i Innovació Parc Tauli (I3PT), CIBERSAM, Mataró, 08304 Barcelona, Spain; [email protected] 3 Department of Psychiatry, University of Toronto, #605 260 Heath St. West, Toronto, ON M5T 1R8, Canada * Correspondence: [email protected] Received: 1 September 2020; Accepted: 12 October 2020; Published: 16 October 2020 Abstract: Sleep disturbances accompany almost all mental illnesses, either because sound sleep and mental well-being share similar requisites, or because mental problems lead to sleep problems, or vice versa. The aim of this narrative review was to examine sleep in patients with delusions, particularly in those diagnosed with delusional disorder. We did this in sequence, first for psychiatric illness in general, then for psychotic illnesses where delusions are prevalent symptoms, and then for delusional disorder. The review also looked at the effect on sleep parameters of individual symptoms commonly seen in delusional disorder (paranoia, cognitive distortions, suicidal thoughts) and searched the evidence base for indications of antipsychotic drug effects on sleep. It subsequently evaluated the influence of sleep therapies on psychotic symptoms, particularly delusions. The review’s findings are clinically important. Delusional symptoms and sleep quality influence one another reciprocally. Effective treatment of sleep problems is of potential benefit to patients with persistent delusions, but may be difficult to implement in the absence of an established therapeutic relationship and an appropriate pharmacologic regimen.
    [Show full text]
  • Early Identification of Psychosis a Primer
    Early Identification of Psychosis A Primer Mental Health Evaluation & Community Consultation Unit TABLE OF CONTENTS Introduction...............................................................................................................3 Psychosis and Early Intervention........................................................................4 Why is Early Intervention Needed?...................................................................5 Risk and Onset..........................................................................................................6 Course of First-Episode Psychosis 1. Prodrome........................................................................................................7 2. Acute Phase....................................................................................................8 3. Recovery Phase..............................................................................................9 Summary of First-Episode Psychosis...............................................................11 Tips for Helpers......................................................................................................12 More Resources......................................................................................................15 Acknowledgements...............................................................................................16 2 INTRODUCTION Psychosis is a condition characterized by loss of contact with reality and may involve severe disturbances in perception, cognition, behavior,
    [Show full text]